IL-2 variant polypeptides and compositions comprising one or more IL-2 variant polypeptides, e.g., fusion polypeptides, having reduced affinity to IL-2R and IL-2R are disclosed, as well as method for their use, e.g., in treatments involving cancer vaccines, TCR-T cell therapy and CAR-T cell therapy. Such polypeptides do not systemically activate multiple immune cell subsets, as native IL-2 delivered in high doses would, but rather predominantly activate only T cells whose T cell receptors (TCRs) are engaged with a peptide-MHC complex (pMHC) presented by an antigen presenting cell, which can thus provide a useful therapeutic index for pharmaceutical compositions comprising such polypeptides.

Embodiments are directed to nanofiber compositions comprising antigens, such as the fusion peptide (FP) of HIV-1 trimers. The compositions may be used as vaccines themselves, or they may be used in combination with vaccines to enhance the immune response and increase antibody titers.

The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments.

The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

The present disclosure provides mRNAs encoding an IL 15 fusion protein comprising an IL 15 polypeptide, an IL 15R polypeptide, and an ApoA polypeptide and methods of treating cancer, including solid tumors and disseminated cancers such as myeloid malignancies, using the mRNAs described herein, optionally formulated as lipid nanoparticles.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which specific Interleukin-1 mutein antigens, IL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against IL-1.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which preferably comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which specific feline Interleukin-1 mutein antigens, fIL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against fIL-1.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and/or glutamic acid to which canine Interleukin-1 mutein antigens, cIL-1-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against cIL-1.

Provided herein, inter alia, nucleic acids including coding sequences for human CD80, IL-15, IL-15R polypeptides, wherein the coding sequence for hCD80 is operably positioned upstream to the coding sequences for hIL-15 and hIL-15R. The disclosure also provides recombinant cells, cell cultures, pharmaceutical compositions, and whole-cell vaccines containing the recombinant cells disclosed herein. Also disclosed are methods useful for treating myeloma and leukemias, such as acute myelogenous leukemia (AML).

A vaccine composition for immunizing and/or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.

The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines, in particular against the endogenous IL-4, IL-5, IL-13, IL-31 and IL-33 proteins in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments.

The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.